Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To evaluate if a flexible dose escalation of lacosamide, up to the maximum approved dose of
400 mg/day, or to a clinically effective lower dose for an individual patient, improves the
tolerability and safety of lacosamide (200 mg to 400 mg/d) as add-on treatment for patients
with partial onset epilepsy.
Explanation of acronym: SELF = Safety Efficacy Lacosamide Flexibility